Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. No specific details or discussions about raising funds via equity or debt instruments were provided during the Q1 FY25 earnings call. The focus was primarily on capacity expansions (Xanthine project, Atali project) and operational updates funded through internal accruals or ongoing CAPEX plans. Total CAPEX guidance for FY25 is around Rs. 500-550 crores, including Rs. 150 crores for Xanthine and Rs. 375 crores for the Atali project, with no mention of external fundraising. Management has not indicated any

Future growth expectations in sales/revenue/volumes?

CDMO/CMO business expects strong growth of 25% to 30% year-on-year in FY25 driven by increased inquiries and projects due to US Biosecure Act and China Plus One strategies. Expansion projects like Atali facility commissioning by Q4 FY25 will add 400-500 KL capacity, increasing capacity by about 25-30%, supporting future demand surge. Xanthine segment capacity is being expanded to 9000 MT by early FY26, addressing demand growth. Semi-commercial block at Vapi site operational in Q2 FY25 will enable small to medium batch size productions. Despite competition in Xanthine prices, export share grew

Future growth expectations in earnings/operating earnings/profits/EPS?

Company maintains guidance of approximately 10% to 12% EBITDA growth in FY25. Long-term goal is around 15% annual growth in earnings over the next three years. CDMO/CMO segment expected to grow strongly by 25% to 30% year-on-year in FY25, driven by new projects and expanded capacity. Xanthine business to expand capacity targeting 9000 metric tonnes by FY26, enhancing volumes and revenues. Atali project commissioning by Q4 FY25 will add 25-30% capacity, aiding volume growth and improving margin profile. Gross margins expected to stabilize with improved CDMO contribution but remain sub

Current/ Expected Orderbook/ Pending Orders?

The company currently has 53 live projects with 18 customers, up from 16 commercial projects six months ago. There is a strong pipeline of early-phase projects indicating good future growth. Recent quarters saw an increase in project additions, reflecting higher traction and inquiries. Commercial projects account for around 27, with over 50-60% in early stages. CDMO/CMO business had a base revenue of Rs. 170 crore in FY24; guidance for a 25-30% growth over that in FY25. Project sizes vary, with some inquiries exceeding $1-2 million, but many projects are still ramping up post-validat

Aarti PharmaQ1 FY25Pharmaceuticals & Biotechnology

Aarti Pharma Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹968P/E: 39.6Market Cap: ₹8.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

CDMO/CMO business expects strong growth of 25% to 30% year-on-year in FY25 driven by increased inquiries and projects due to US Biosecure Act and China Plus One strategies.
Expansion projects like Atali facility commissioning by Q4 FY25 will add 400-500 KL capacity, increasing capacity by about 25-30%, supporting future demand surge.
Xanthine segment capacity is being expanded to 9000 MT by early FY26, addressing demand growth.
Semi-commercial block at Vapi site operational in Q2 FY25 will enable small to medium batch size productions.
Despite competition in Xanthine prices, export share grew to 57% this quarter, indicating volume growth potential.
The Company aims for consolidated EBITDA growth of 10%-12% in FY25 and a long-term annual growth target of approximately 15%.
Multi-stage CDMO projects' growth expected as more projects move from early to commercial stages.

Margin guidance

Category 3

Company maintains guidance of approximately 10% to 12% EBITDA growth in FY25.
Long-term goal is around 15% annual growth in earnings over the next three years.
CDMO/CMO segment expected to grow strongly by 25% to 30% year-on-year in FY25, driven by new projects and expanded capacity.
Xanthine business to expand capacity targeting 9000 metric tonnes by FY26, enhancing volumes and revenues.
Atali project commissioning by Q4 FY25 will add 25-30% capacity, aiding volume growth and improving margin profile.
Gross margins expected to stabilize with improved CDMO contribution but remain subject to competitive pressures, especially in API and Xanthine segments.
Margin impact from trading business shutdown will be minimal due to low margin profile (1-2%).
Continued investment in R&D and capacity expansions to support sustained growth and profitability.

See what Aarti Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
No specific details or discussions about raising funds via equity or debt instruments were provided during the Q1 FY25 earnings call.
The focus was primarily on capacity expansions (Xanthine project, Atali project) and operational updates funded through internal accruals or ongoing CAPEX plans.
Total CAPEX guidance for FY25 is around Rs. 500-550 crores, including Rs. 150 crores for Xanthine and Rs. 375 crores for the Atali project, with no mention of external fundraising.
Management has not indicated any intentions to raise additional capital through the markets as of this call.

Order book

Yes

The company currently has 53 live projects with 18 customers, up from 16 commercial projects six months ago.
There is a strong pipeline of early-phase projects indicating good future growth.
Recent quarters saw an increase in project additions, reflecting higher traction and inquiries.
Commercial projects account for around 27, with over 50-60% in early stages.
CDMO/CMO business had a base revenue of Rs. 170 crore in FY24; guidance for a 25-30% growth over that in FY25.
Project sizes vary, with some inquiries exceeding $1-2 million, but many projects are still ramping up post-validation.
The company anticipates ongoing demand growth supported by capacity expansions such as the Atali facility and flexible plant utilisation.

See what Aarti Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes

- **Xanthine Expansion:** Approx. Rs. 150 crore CAPEX planned for expanding Xanthine production capacity from 5000 to 9000 metric tonnes across two sites, expected completion by early FY26. - **Atali Project:** Rs. 375 crore outlay for Atali facility focused on CDMO/CMO and Intermediate manufacturing, expected to commission by Q4 FY25; will add 400–500 KL capacity, increasing overall capacity by 25-30%. - **Vapi Site Expansion:** Semi-commercial block for small to medium batch sizes commissioning expected in Q2 FY25 to support early phase CDMO/CMO projects. - **Solar Power Plant:** Rs. 90 crore investment in a new solar power plant at Akola, Maharashtra, expected to commission in the current quarter and cover one-third of power requirements, reducing manufacturing costs. - **Total FY25 CAPEX:** Estimated Rs. 500-550 crore encompassing the above projects. These investments aim to drive capacity expansion, support CDMO business growth, and improve cost efficiencies.

Track Aarti Pharma — get its next earnings analysis in your feed

How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAarti Pharma

Rev 2Mar 3

See where Aarti Pharma sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Aarti Pharma rank in Pharmaceuticals & Biotechnology?

Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Aarti Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →